Investigation of the effects of the exosomes on patients with COVID-19

Phase 2

• Conditions: COVID-19.; COVID-19; U07.1

• Registration Number: IRCT20130812014333N164
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

Infected patients with Corona virus based on CRISPR test (PCR)
Diagnosis of acute respiratory syndrome according to Berlin criteria
Requires oxygenation or confirmed pneumonia by radiologically or CT
Oxygen uptake concentration
Progression of of pulmonary edema more than 50% within 24-48 hours
Mild to moderate pneumonia caused by a new coronavirus

Exclusion Criteria

Serious underlying illness or psychosis
Co-infection with HIV, tuberculosis, influenza virus, adenovirus and other viral respiratory infections
Liver or kidney SOFA score more than 3

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxygen saturation. Timepoint: 2 to 3 days after injection,daily for two weeks. Method of measurement: Using a pulse oximeter.;Neutrophil to lymphocyte ratio. Timepoint: 2 to 3 days after injection,daily for two weeks. Method of measurement: Using a blood test (To determine the percentage of neutrophils and lymphocytes, the optical method or light microscope and Giemsa staining is used).;Ferritin. Timepoint: 2 to 3 days after injection,daily for two weeks. Method of measurement: Using a blood test and Chemiluminescence immunoassay method.